Adaptimmune Therapeutics is prepping for another FDA submission after 42% of patients with sarcoma responded to the company's investigational cell therapy in a pivotal phase 2 trial. The primary analysis includes 64 patients with previously treated, advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS). The open-label study, dubbed IGNYTE-ESO, is evaluating lete-cel, Adaptimmune’s engineered T-cell receptor therapy. Source: Fierce Biotech 13/11/2024